BANK VONTOBEL/CALL/NOVO NORDISK ADR B/110/0.1/21.06.24 | Delayed Deutsche Boerse AG 08:14:42 08/05/2024 pm IST | ||
| 1.78 EUR | +2.30% |
|
| Current month | -9.84% | ||
| 1 month | -0.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/24/08 | 1.78 | +2.30% | 0 |
| 07/24/07 | 1.74 | +20.83% | 0 |
| 06/24/06 | 1.44 | +2.13% | 0 |
| 03/24/03 | 1.41 | -11.32% | 0 |
| 02/24/02 | 1.59 | -17.62% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 08, 2024 at 08:14 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM31BP |
| ISIN | DE000VM31BP7 |
| Date issued | 16/10/2023 |
| Strike | 110 $ |
| Maturity | 21/06/2024 (44 Days) |
| Parity | 10 : 1 |
| Emission price | 0.99 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.66 € |
|---|---|
| Lowest since issue | 0.37 € |
| Spread | 0.01 € |
| Spread % | 0.57% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
882.6
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.95%
- Stock Market
- Warrants
- Warrant